ALT5 Sigma (NASDAQ:AIFC) Posts Earnings Results

ALT5 Sigma (NASDAQ:AIFC) released its quarterly earnings data on Monday. The company reported ($2.14) earnings per share (EPS) for the quarter, FiscalAI reports. ALT5 Sigma had a negative net margin of 1,386.90% and a negative return on equity of 50.52%. The business had revenue of $4.71 million during the quarter.

ALT5 Sigma Stock Down 9.6%

NASDAQ:AIFC traded down $0.10 during mid-day trading on Monday, hitting $0.91. 1,098,372 shares of the stock were exchanged, compared to its average volume of 3,399,894. The firm’s 50-day simple moving average is $1.11 and its 200 day simple moving average is $1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.57 and a current ratio of 0.57. ALT5 Sigma has a fifty-two week low of $0.73 and a fifty-two week high of $10.95.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, ALT5 Sigma currently has a consensus rating of “Sell”.

Institutional Trading of ALT5 Sigma

Several hedge funds have recently added to or reduced their stakes in AIFC. Crcm LP lifted its holdings in ALT5 Sigma by 373.2% during the 4th quarter. Crcm LP now owns 10,941,280 shares of the company’s stock worth $12,035,000 after purchasing an additional 8,629,103 shares during the last quarter. Vanguard Group Inc. lifted its holdings in ALT5 Sigma by 775.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,126,395 shares of the company’s stock worth $16,480,000 after purchasing an additional 5,426,519 shares during the last quarter. Prelude Capital Management LLC acquired a new stake in ALT5 Sigma during the 3rd quarter worth approximately $6,216,000. NWI Management LP bought a new position in ALT5 Sigma during the 3rd quarter worth $4,842,000. Finally, Alyeska Investment Group L.P. bought a new position in ALT5 Sigma during the 3rd quarter worth $4,697,000. 6.27% of the stock is owned by institutional investors and hedge funds.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.